Evaluation of Serum miR-17-92 Cluster as Noninvasive Biomarkers for Bladder Cancer Diagnosis

Wang, Jingyao; Peng, Xiqi; Li, Rongkang; Liu, Kaihao; Zhang, Chunduo; Chen, Xuan; Huang, Guoxin; Zhao, Liwen; Chen, Zebo; Lai, Yongqing

doi:10.3389/fonc.2021.795837

Cited by 11 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of miRNAs is closely related to the sensitivity of lung cancer radiotherapy [ 30 ]. miR-92a-3p is an essential member of the miR-17-92 cluster [ 31 ]. The miR-17-92 cluster is reported to have tumor suppressor or tumor-promoting roles in different types of tumors.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics Analysis for Identifying Differentially Expressed MicroRNAs Derived from Plasma Exosomes Associated with Radiotherapy Resistance in Non-Small-Cell Lung Cancer

Zeng¹,

Zeng

Ye³

2022

Applied Bionics and Biomechanics

View full text Add to dashboard Cite

Objective. To explore the differentially expressed microRNAs (DEmiRs) derived from plasma exosomes related to radiotherapy resistance and their corresponding pathways in non-small-cell lung cancer (NSCLC). Methods. Plasma samples from NSCLC patients were retrieved and analyzed. The patients were divided into 3 groups based on the tumor regression grade criteria, assessed by radiological imaging after radiotherapy. TRG1 referred to tumor shrinkage of ≤30% after radiotherapy, TRG2 as 30 % < TRG < 50 % , and TRG3 as TRG ≥ 50 %. High-throughput sequencing and bioinformatics analysis were used to compare the DEmiRs between the three groups. The miRanda, PITA, and RNAhybrid software were used to identify potential target genes of the DEmiRs. GO function enrichment and KEGG pathway enrichment analyses were performed on the target gene set. Results. There were 24 DEmiRs (12 were upregulated and 12 downregulated) between the TRG1 and TRG2 groups, 11 between the TRG1 and TRG3 groups (6 upregulated and 5 downregulated), and 35 between the TRG2 and TRG3 groups. The common DEmiRs between the three groups were miR-92a-3p. GO analysis showed that the target genes of the DEmiRs were mainly enriched in unicellular organism processes, cell transformation, cell localization, and their establishment. KEGG enrichment analysis showed that target genes were significantly enriched in the Ras signaling pathway and associated with endocytosis. Among the 135 identified target genes of miR-92a-3p, 4 were involved in the PI3K-Akt signaling pathway (the downstream pathway of the Ras gene) and 3 in the cAMP signaling pathway (the upstream pathway of the Ras gene). Further, 2 other target genes were involved in the Rap1 signaling pathway (the upstream pathway of PI3K-Akt). Conclusion. By assessing the expression and functional profile of DEmiRs in the plasma exosomes of NSCLC patients after radiotherapy, miR-92a-3p was identified as a promising target affecting radiotherapy outcomes through the Ras signaling pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Bioinformatics Analysis for Identifying Differentially Expressed MicroRNAs Derived from Plasma Exosomes Associated with Radiotherapy Resistance in Non-Small-Cell Lung Cancer

Zeng¹,

Zeng

Ye³

2022

Applied Bionics and Biomechanics

View full text Add to dashboard Cite

show abstract

“…The significance of the diagnosis of liquid biopsy had been highlighted in the last decade. Liquid biopsy could act as a promising method for precise treatment and monitoring of treatment response in realtime [23]. Moreover, liquid biomarkers in serum could be used for the diagnosis of many diseases [10,24].…”

Section: Discussionmentioning

confidence: 99%

The diagnostic value of serum miR-17-92 cluster in ischemic stroke

Dong,

Ye,

Huang

et al. 2024

View full text Add to dashboard Cite

Introduction: Ischemic stroke (IS) is a prevalent disease that poses a significant threat to human life and is responsible for a substantial financial burden. Research has established the crucial role of the miR-17-92 cluster in lung cancer, cardiovascular diseases, and traumatic brain injury. Despite this, few research studies had fully detected the potential of the miR-17-92 cluster as a novel circulating marker for diagnosing IS. Material and methods: miR-17-92 cluster expression in IS was investigated using GSE117064 dataset via bioinformatics analysis. Moreover, qRT-PCR was conducted to further verify miR-17-92 cluster expression in 58 IS individuals and 50 healthy controls (HCs). These cluster members were examined regarding their potential for detecting and diagnosing IS using the ROC method.Results: The expression level of serum miR-20a-5p, miR-19a-3p, miR-18a-5p, and miR-19b-3p was considerably lowered in IS in contrast with HC in both the GSE117064 cohort and clinical cohort. Moreover, these four miRNAs had a fair performance in IS detection. Thereafter, a diagnostic model based on these aforementioned four miRNAs was developed by logistic regression, which had an AUC of 0.974 in the ROC curve. This diagnostic module was verified using the GSE117064 dataset. Further analysis demonstrated an increasing level of the aforementioned miRNAs in day-7 IS patients compared with day-1 IS patients. Conclusions: This research verified the downregulation of the miR-17-92 cluster in IS. This diagnostic model enrolling four cluster members may be a promising biomarker for IS detection.

show abstract

“…In a comprehensive study of using microarrays, a diagnostic combination of seven miRNAs showed an exceptional accuracy in distinguishing BC from noncancerous conditions and other tumor types; this combination used in BC patients with low-grade stage and < pT2 stage demonstrated a remarkable sensitivity (92.7% and 94.7%, respectively), surpassing the effectiveness of urine cytology as indicated by a significantly higher area under the curve (AUC) [39] . However, it should be noted that this combination fails to differentiate between NMBC and MIBC, which is crucial information for determining the necessity of cystectomy.…”

Section: Mirna In Bloodmentioning

confidence: 99%

Potential clinical application of microRNAs in bladder cancer

Wang,

Wei,

et al. 2024

J Biomed Res

View full text Add to dashboard Cite

Bladder cancer (BC) ranks the tenth most prevalent malignancy globally, presenting significant clinical and societal challenges because of its high incidence, rapid progression, and frequent recurrence. Presently, cystoscopy and urine cytology serve as the established diagnostic methods for BC. However, their efficacy is limited by invasive nature and low sensitivity. Therefore, the development of highly specific biomarkers and effective non-invasive detection strategies is imperative for achieving a precise and timely diagnosis of BC, as well as for facilitating an optimal tumor treatment and an improved prognosis. microRNAs (miRNAs), short noncoding RNA molecules spanning around 20-25 nucleotides, are implicated in the regulation of diverse carcinogenic pathways. Substantially altered miRNAs form robust functional regulatory networks that exert a notable influence on the tumorigenesis and progression of BC. Investigations into aberrant miRNAs derived from blood, urine, or extracellular vesicles indicate their potential roles as diagnostic biomarkers and prognostic indicators in BC, enabling miRNAs to monitor the progression and predict the recurrence of the disease. Simultaneously, the investigation centered on miRNA as a potential therapeutic agent presents a novel approach for the treatment of BC. This review provides a comprehensive analysis of biological roles of miRNAs in tumorigenesis and progression, systematically summarizes the potential as diagnosis and prognosis biomarkers as well as therapeutic targets for BC. Additionally, we evaluate the progress made in laboratory techniques within this field and discuss the prospects.

show abstract

Evaluation of Serum miR-17-92 Cluster as Noninvasive Biomarkers for Bladder Cancer Diagnosis

Cited by 11 publications

References 27 publications

Bioinformatics Analysis for Identifying Differentially Expressed MicroRNAs Derived from Plasma Exosomes Associated with Radiotherapy Resistance in Non-Small-Cell Lung Cancer

Bioinformatics Analysis for Identifying Differentially Expressed MicroRNAs Derived from Plasma Exosomes Associated with Radiotherapy Resistance in Non-Small-Cell Lung Cancer

The diagnostic value of serum miR-17-92 cluster in ischemic stroke

Potential clinical application of microRNAs in bladder cancer

Contact Info

Product

Resources

About